Intensive management reduced disease activity in rheumatoid arthritis

November 2004
ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p70
Academic Journal
The article addresses the question whether in patients with rheumatoid arthritis (RA), intensive management (IM) is more effective than routine care (RC) for reducing disease activity. In the study, patients in the IM group began treatment with a new DMARD and were seen monthly by the same rheumatologist for injection of up to 3 swollen joints with triamcinolone acetonide up to 120 mg per visit. The article concludes that in patients with rheumatoid arthritis, intensive management reduced disease activity and slowed radiographic progression more than routine care.


Related Articles

  • COMMENTARY: Intensive management reduced disease activity in rheumatoid arthritis. Heijde, Dé;sirée van der // ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p70 

    The article presents a commentary on the study, which concluded that Intensive management reduced disease activity in rheumatoid arthritis (RA). The study emphasizes the need to measure treatment effects and to change management as necessary. While rheumatologists are well aware of the need for...

  • Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Chambers, Christina; Koren, Gideon; Tutuncu, Zuhre N.; Johnson, Diana; Jones, Kenneth L. // Canadian Family Physician;Mar2007, Vol. 53 Issue 3, p409 

    QUESTION I have a patient planning pregnancy who has resistant rheumatoid arthritis that will require treatment with some of the new" medications. Which ones are safe to use during pregnancy, and which ones do we know enough about to tell whether they are safe or not? ANSWER For most new...

  • Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Alten, Rieke; Krüger, Klaus; Rellecke, Julian; Schiffner-Rohe, Julia; Behmer, Olaf; Schiffhorst, Guido; Nolting, Hans-Dieter // Patient Preference & Adherence;Nov2016, Vol. 10, p2217 

    Background: Biological disease-modifying antirheumatic drugs (bDMARDs) used in second-line treatment of rheumatoid arthritis (RA) are administered parenterally. However, so-called targeted synthetic DMARDs (tsDMARDs) - developed more recently - offer alternative (ie, oral) administration forms...

  • EULAR updates recommendations for DMARDs in RA.  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p3 

    The article reports that the European League Against Rheumatism (EULAR) has updated its recommendation for the use of disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA), aimed at improving outcomes in patients with RA.

  • POP QUIZ: …on Rheumatoid Arthritis Answers and Explanations.  // Cortlandt Forum;Jul2006, Vol. 19 Issue 7, p93 

    Answers and explanations to a quiz on rheumatoid arthritis (RA) in the United States are presented. Around 1% of the U.S. population is affected by RA. The disease is characterized by symmetrical additive polyarthritis. The kidney is usually spared in RA. Medications show to stop progression of...

  • The problem with potency. Scott, Christopher Thomas // Nature Biotechnology;Sep2005, Vol. 23 Issue 9, p1037 

    The article presents information on side effects related to monoclonal antibodies used in therapeutics. As the $30 billion monoclonal antibody market moves from murine-based to chimeric and fully human products, it grows at a compounded clip of nearly 20% per year. John Shields, an immunologist...

  • Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid Arthritis: A Review. Nichol, M.B.; Harada, A.S.M. // PharmacoEconomics;1999, Vol. 16 Issue 5, p433 

    As the treatment of rheumatoid arthritis (RA) moves towards earlier and more consistently maintained therapy, often with highly toxic medications, the importance of assessing patients' health-related quality of life (HR-QOL) is of increasing concern to healthcare providers, insurers and...

  • THERAPEUTIC STRATEGIES FOR RHEUMATOID ARTHRITIS. Smolen, Josef S.; Steiner, Günter // Nature Reviews Drug Discovery;Jun2003, Vol. 2 Issue 6, p473 

    Recent years have seen considerable advances in our understanding of both the clinical and basic-research aspects of rheumatoid arthritis. Clinical progress has come from a better recognition of the natural history of the disease, the development and validation of outcome measures for clinical...

  • The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study. Suda, Akiko; Nagaoka, Shouhei; Ohono, Shigeru; Ideguchi, Haruko; Soga, Takayoshi; Ishigatsubo, Yoshiaki // Modern Rheumatology (Springer Science & Business Media B.V.);Dec2008, Vol. 18 Issue 6, p609 

    We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics